Could a single dose beat brain worms? new trial aims to find out
NCT ID NCT06565507
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called oxfendazole for people with mild brain cysticercosis, a parasitic infection that can cause seizures. Researchers will compare a single dose and three doses of oxfendazole against the standard combination therapy. The goal is to see if oxfendazole clears the parasites better and reduces seizure relapses. The trial plans to enroll 544 adults aged 18 to 75.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- oxfendazole
- What this could lead to
- If it works, this could provide a simpler, single-dose treatment for brain cysticercosis, reducing the need for longer drug regimens.
- What could go wrong
- This is a Phase 2/3 trial, so results are not yet known. The drug may not work better than current treatments, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 544 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female individuals between 18 and 75 years of age, with suspected viable or degenerating intraparenchymal brain cysticercosis on neuroimaging (CT or MRI) and fulfill the diagnostic criteria for solitary cysticercus granuloma (Rajshekhar and Chandy, 1997) 2. If female of child-bearing potential and men, willing to use an adequate method of contraception\*, including implants, injectables, combined oral contraceptives, effective intrauterine devices, sexual abstinence, or vasectomized partner while participating in the study. 3. Patients with normal laboratory values for hemoglobin, platelet counts, total white blood cells, glucose, creatinine, bilirubin, ALT, and AST. 4. Availability to grant informed consent. Exclusion Criteria: 1. Multiple lesion sites or more than two adjacent lesions. 2. Suspected neurotuberculosis (Rajshekhar's criteria) \[66,67\] 3. More than two viable brain cysts. 4. Large brain cysts (\> 3cm in diameter) 5. Subarachnoid neurocysticercosis or intraventricular 6. Untreated ocular cysticercosis 7. Previous therapy with ABZ (does not include patients who received single-dose 400 mg ABZ for intestinal parasites), or PZQ in the past twelve months. 8. Active pulmonary tuberculosis evidenced by a positive chest X-ray and positive sputum smears. 9. Systemic disease other than NCC that may affect therapy or short-term prognosis, including but not limited to chronic renal failure, hepatic insufficiency, cardiac failure, and steroid-dependent immune diseases. 10. Patients in unstable condition or with severe intracranial hypertension (ICH). Definition of severe ICH for this study would be the presence of headaches, nausea, and vomiting, and papilledema at fundoscopic examination. 11. Pregnancy 12. History of hypersensitivity to ABZ or PZQ 13. Concurrent treatment with cimetidine, ranitidine, or theophylline. 14. Chronic alcohol or drug abuse. 15. Positive to Strongyloides infection 16. History of reported allergy to contrast substances used in MRI.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain cysticercosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.